

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> MAY 9 2003 (use as many sheets as necessary)		<b>Complete if Known</b>	
Application Number		10/028, 156	
Filing Date		12/21/2001	
First Named Inventor		ROGER A. SABBADINI	
Group Art Unit		1654	
Examiner Name			
Attorney Docket Number		078853-0304	

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
LL	A1	5,989,803		Tabas et al.	November 23, 1999	CLASS 435 / 4 SUB

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
LL	A2	WO	01 37836 A		Emory University	May 31, 2001		
LL	A3	WO	01 71045		Millennium Pharmaceuticals, Inc.	Sept. 27, 2001		
LL	A4	WO	00 56135		Regents of the University of California	Sept. 28, 2000		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
LL	A5	Sabbadini et al., "The MIRF trial: Predicting the incidence and severity of CAD using serum sphingolipids." Circulation, 102: 11699, 2000 (Abstract).	
LL	A6	Nakajima et al., "Expression and characterization of Edg-1 receptors in rat cardiomyocytes: Calcium deregulation in response to sphingosine 1-phosphate." European Journal of Biochemistry, 267: 5679-5686, 2000.	
LL	A7	Huwiler et al., "Physiology and pathophysiology of sphingolipid metabolism and signaling." Biochimica Et Biophysica Acta, 1485: 63-99, 2000.	
LL	A8	International Search Report issued in PCT Application No. PCT/US01/50785	

Examiner Signature	<i>Louise Green</i>	Date Considered	10/04
--------------------	---------------------	-----------------	-------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.